Zenas BioPharma

Zenas is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late-stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas' lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. We believe that obexelimab's unique mechanism of action and self-administered, subcutaneous injection regimen may broadly and effectively...

A leading biopharmaceutical company seeks an Associate Director, Medical Science Liaison, specifically for Rheumatology. This role involves engaging with healthcare professionals to educate them on the company's product portfolio, supporting clinical research efforts, and maintaining vital relationships with key opinion leaders in the field. The ideal candidate will possess an advanced clinical degree and experience in a field-based or clinical position, while demonstrating strong communication and interpersonal skills. Compensation ranges between $181,600 to $227,000. #J-18808-Ljbffr

Associate Director, Medical Science Liaison (MSL), Rheumatology – Zenas BioPharma Territory: Northwest (AK, NE, SD, ND, MT, WY, CO, UT, ID, WA, OR) Zenas is a clinical‑stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative therapies for patients with autoimmune diseases. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas is advancing two late‑stage, potential franchise molecules, obexelimab and orelabrutinib. Obexelimab, Zenas’ lead product candidate, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated in many autoimmune diseases without...